Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TACR1 | P25103 | 1/20 | 0.58 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073757 | 0.90 | KCNJ1 (0.57) | ALDH1A1SMN1; SMN2HPGDTACR1KCNJ1 | |
| Hydrochloric Acid SCHEMBL7564284 | 0.88 | KCNJ1 (0.58) | ALDH1A1SMN1; SMN2HPGDTACR1KCNJ1 | |
| SCHEMBL7422612 | 0.86 | TACR1 (0.58) | ALDH1A1SMN1; SMN2HPGDTACR1KCNJ1 | |
| SCHEMBL922716 | 0.86 | KCNJ1 (0.74) | ALDH1A1SMN1; SMN2HPGDTACR1KCNJ1 | |
| SCHEMBL8718280 | 0.85 | KCNJ1 (0.61) | ALDH1A1SMN1; SMN2HPGDTACR1KCNJ1 | |
| SCHEMBL8715361 | 0.85 | KCNJ1 (0.55) | ALDH1A1SMN1; SMN2HPGDTACR1KCNJ1 | |
| SCHEMBL20272178 | 0.83 | MAPT (0.60) | ALDH1A1SMN1; SMN2TACR1KCNJ1KDM4E | |
| SCHEMBL17979918 | 0.82 | LMNA (0.51) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1HTR6 | |
| SCHEMBL25416781 | 0.81 | CTSB (0.71) | ALDH1A1SMN1; SMN2KDM4EHTTHTR6 | |
| SCHEMBL14999775 | 0.81 | CDK1 (0.50) | ALDH1A1SMN1; SMN2KCNJ1KDM4EHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001046170-A1 | AMIDINE DERIVATIVES WHICH ARE INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137736-A1 | N-(4-methoxy-3-((methylamino)methyl)phenyl)-2 -thiophenecarboximidamide, for example; nitric oxide synthase inhibitors; treating hypoxia, ischemia, stroke, Parkinson's disease, anxiety, schizophrenia, migraine and pain | OPRM1, HIF1AN, MAOB | ALDH1A1 784/4885SMN1; SMN2 610/4885HPGD 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.